|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C3orf38 |
Gene summary for C3ORF38 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C3orf38 | Gene ID | 285237 |
| Gene name | chromosome 3 open reading frame 38 | |
| Gene Alias | C3orf38 | |
| Cytomap | 3p11.1 | |
| Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | Q5JPI3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 285237 | C3orf38 | P74T-E | Human | Esophagus | ESCC | 3.06e-10 | 2.67e-01 | 0.1479 |
| 285237 | C3orf38 | P75T-E | Human | Esophagus | ESCC | 1.69e-30 | 6.56e-01 | 0.1125 |
| 285237 | C3orf38 | P76T-E | Human | Esophagus | ESCC | 1.38e-11 | 1.94e-01 | 0.1207 |
| 285237 | C3orf38 | P79T-E | Human | Esophagus | ESCC | 6.60e-14 | 3.46e-01 | 0.1154 |
| 285237 | C3orf38 | P80T-E | Human | Esophagus | ESCC | 1.66e-27 | 7.20e-01 | 0.155 |
| 285237 | C3orf38 | P82T-E | Human | Esophagus | ESCC | 6.11e-08 | 3.84e-01 | 0.1072 |
| 285237 | C3orf38 | P83T-E | Human | Esophagus | ESCC | 2.83e-20 | 5.59e-01 | 0.1738 |
| 285237 | C3orf38 | P84T-E | Human | Esophagus | ESCC | 3.90e-06 | 3.37e-01 | 0.0933 |
| 285237 | C3orf38 | P89T-E | Human | Esophagus | ESCC | 1.21e-04 | 3.78e-01 | 0.1752 |
| 285237 | C3orf38 | P107T-E | Human | Esophagus | ESCC | 5.21e-10 | 2.47e-01 | 0.171 |
| 285237 | C3orf38 | P127T-E | Human | Esophagus | ESCC | 1.25e-08 | 7.48e-02 | 0.0826 |
| 285237 | C3orf38 | P128T-E | Human | Esophagus | ESCC | 8.43e-16 | 5.39e-01 | 0.1241 |
| 285237 | C3orf38 | P130T-E | Human | Esophagus | ESCC | 1.37e-15 | 3.27e-01 | 0.1676 |
| 285237 | C3orf38 | C21 | Human | Oral cavity | OSCC | 1.18e-18 | 6.09e-01 | 0.2678 |
| 285237 | C3orf38 | C30 | Human | Oral cavity | OSCC | 6.15e-08 | 5.06e-01 | 0.3055 |
| 285237 | C3orf38 | C38 | Human | Oral cavity | OSCC | 2.61e-04 | 7.06e-01 | 0.172 |
| 285237 | C3orf38 | C43 | Human | Oral cavity | OSCC | 4.12e-05 | 1.58e-01 | 0.1704 |
| 285237 | C3orf38 | C46 | Human | Oral cavity | OSCC | 4.76e-18 | 4.32e-01 | 0.1673 |
| 285237 | C3orf38 | C57 | Human | Oral cavity | OSCC | 4.48e-14 | 3.64e-01 | 0.1679 |
| 285237 | C3orf38 | LN46 | Human | Oral cavity | OSCC | 3.21e-20 | 6.84e-01 | 0.1666 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C3orf38 | SNV | Missense_Mutation | c.686N>T | p.His229Leu | p.H229L | Q5JPI3 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A1-A0SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C3orf38 | SNV | Missense_Mutation | novel | c.704N>A | p.Gly235Glu | p.G235E | Q5JPI3 | protein_coding | tolerated(0.05) | benign(0.009) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| C3orf38 | SNV | Missense_Mutation | rs139365680 | c.416N>A | p.Arg139His | p.R139H | Q5JPI3 | protein_coding | tolerated(0.86) | benign(0.001) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C3orf38 | SNV | Missense_Mutation | novel | c.179N>G | p.Leu60Arg | p.L60R | Q5JPI3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| C3orf38 | SNV | Missense_Mutation | c.532N>T | p.Leu178Phe | p.L178F | Q5JPI3 | protein_coding | deleterious(0.03) | probably_damaging(0.982) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C3orf38 | SNV | Missense_Mutation | c.460N>C | p.Asn154His | p.N154H | Q5JPI3 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-EI-6508-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| C3orf38 | deletion | Frame_Shift_Del | c.645delC | p.Asn216ThrfsTer2 | p.N216Tfs*2 | Q5JPI3 | protein_coding | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| C3orf38 | insertion | Frame_Shift_Ins | novel | c.632_633insG | p.Leu213SerfsTer39 | p.L213Sfs*39 | Q5JPI3 | protein_coding | TCGA-AG-A020-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Chemotherapy | folinic | CR | ||
| C3orf38 | SNV | Missense_Mutation | novel | c.302N>G | p.Lys101Arg | p.K101R | Q5JPI3 | protein_coding | tolerated(0.37) | benign(0.001) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C3orf38 | SNV | Missense_Mutation | novel | c.601N>T | p.Arg201Cys | p.R201C | Q5JPI3 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |